Introduction {#Sec1}
============

Visceral leishmaniasis (VL), also known as Kala-Azar, is a disseminated protozoal infection caused principally by *Leishmania donovani* and *Leishmania infantum* (synonym *Leishmania chagasi* in South America). Occasionally, *Leishmania tropica* in the Middle East and *Leishmania amazonensis* in South America can produce VL \[[@CR1]\].

*Leishmania* spp. are transmitted through the bite of female haematophageous sand flies from the genus *Phlebotomus* in the Old World and *Lutzomyia* in the New World. Depending on the transmission characteristics, two types of VL have been described. The zoonotic form, caused mainly by *L.* *infantum*, with dogs as the main reservoir, occurs in the Mediterranean Basin, China, the Middle East and South America. The anthroponotic form, with human-to-human transmission without an animal reservoir, caused mainly by *L.* *donovani*, is prevalent in East Africa, Bangladesh, India and Nepal.

The worldwide prevalence of VL is estimated to be 12 million cases, with approximately 0.2 to 0.4 million new VL cases each year. More than 90 % of global VL cases occur in just six countries: India, Bangladesh, Sudan, South Sudan, Brazil and Ethiopia \[[@CR2]\]. Co-infection with HIV and *Leishmania* has been reported in more than 35 countries. Initially, most of the cases were from southwestern Europe, but the number of cases is increasing in Sub-Saharan Africa (particularly in Ethiopia), in Brazil and in South Asia. Co-infection in India still seems not to be a major problem and occurs in \<2 % of VL patients \[[@CR3]\].

Since the late 1940s, the traditional treatment for VL has been the use of pentavalent antimonials. However, in the 1980s, conventional amphotericin B deoxycholate was introduced, followed by lipid formulations of amphotericin B---mainly liposomal amphotericin B---with high efficacy and low toxicity. Paromomycin was then incorporated as a cheap and effective parenteral drug, which can be easily administered as an intramuscular (IM) injection. Later, miltefosine was developed as an oral drug option for VL. Nonetheless, clear differences in the clinical efficacy of these drugs have been observed and are based on several factors, which must be taken into consideration in treatment decisions, such as the geographical area of the infection \[[@CR4]\], development of resistance (a striking fact in the case of pentavalent antimonials in India over the last couple of decades \[[@CR5], [@CR6]\]), HIV--*Leishmania* co-infection, malnourishment and other concomitant infections \[[@CR6]\]. These conditions all modify the best treatment option to cure the patient, minimize the occurrence of resistance and decrease the duration of hospitalization, thus reducing costs \[[@CR4]\].

The objectives of this article are to make an exhaustive literature review of VL treatment; to analyze the methodology and the results of the reviewed studies; to give treatment recommendations based on the leishmaniasis presentation form, country of origin and *Leishmania* species: and, finally, to stratify the strength of the recommendations on the basis of the Infectious Diseases Society of America (IDSA) grade classification.

Methods {#Sec2}
=======

At the Tropical Medicine Unit of Ramón y Cajal Hospital in Madrid, Spain, the medical literature was searched, using databases such as MEDLINE, EMBASE, the Web of Science and the Cochrane Library database. No limits were placed with respect to the date of publication. No language restrictions were imposed. The chosen search terms were 'visceral leishmaniasis' AND 'treatment' OR 'parenteral treatment' OR 'oral treatment' OR 'azole drugs' OR 'miltefosine' OR 'pentavalent antimonials' OR 'amphotericin B' OR 'liposomal amphotericin' OR 'pentamidine' OR 'paromomycin' OR 'combination therapy'. Other search terms were 'visceral leishmaniasis' AND OR 'HIV', '*L.* *infantum*' OR '*L.* *donovani*' AND 'treatment'.

Bibliographical references from the included studies were also reviewed. The reference sections of primary studies, narrative reviews and systematic reviews were examined to search for additional primary studies that might have been missed during the electronic search.

Initially, only clinical trials were selected, in order to obtain data with the highest-grade evidence. In the absence of good-quality evidence, a second review was conducted in order to obtain cure-rate information. Later searches included original articles where data on results and treatment regimens were shown, such as large case series and multicentre studies, and also case reports when relevant results were reported.

For each of the selected articles, the data that were collected and analysed were the methodology, treatment regimens (doses and duration), cure rates (always using the last cure rate reported after the longest period of follow-up; when not specified, the intention-to-treat cure rate is given; when data on the per-protocol cure rate is known, this is also reported), the country where the study was performed and the *Leishmania* species that was isolated (when they could not be identified, either those species mentioned by the authors as being most common in the area where the study was performed, or those based on data published by the World Health Organization (WHO) \[[@CR7]\] or in other epidemiological studies \[[@CR2]\] were used). Such data were summarized in tables for each of the leishmaniasis forms of presentation that were studied.

On the basis of the methodology and the results of the studies, treatment recommendations were outlined for each leishmaniasis presentation form, country of origin and *Leishmania* species. The strength of such recommendations was stratified on the basis of the IDSA grade classification (Table [1](#Tab1){ref-type="table"}). In this system, the letters A--E signify the strength of the recommendation for or against a therapeutic measure, and the roman numerals I--III indicate the quality of evidence supporting the recommendation \[[@CR8], [@CR9]\]. The strength of the recommendation was determined on the basis of several factors such as the number of studies performed, the methodology of the studies, the number of patients included, whether or not the specific *Leishmania* spp. was isolated, and the time of follow-up.Table 1Infectious Diseases Society of America (IDSA) grade classificationCategory and gradeDefinitionStrength of recommendation AGood evidence to support a recommendation for use BModerate evidence to support a recommendation for use CPoor evidence to support a recommendation DModerate evidence to support a recommendation against use EGood evidence to support a recommendation against useQuality of evidence IEvidence from one or more randomized clinical trials IIEvidence from one or more well designed clinical trials, without randomization; from cohort or case-controlled analytic studies (preferably from \>1 centre); from multiple time series; or from dramatic results from uncontrolled experiments IIIEvidence from opinions of respected authorities, based on clinical experience, descriptive studies or reports from expert committees

Treatment of Visceral Leishmaniasis {#Sec3}
===================================

Monotherapy {#Sec4}
-----------

Studies of monotherapy for visceral leishmaniasis are listed in Table [2](#Tab2){ref-type="table"}.Table 2Monotherapy for visceral leishmaniasisReferenceCountry; *Leishmania* spp.Type of studyRegimen administeredCure rate (CR)**Oral regimens***Mitefosine*Sundar et al. \[[@CR127]\]India*; L.* *donovani*Pilot phase I/II miltefosine safety and efficacy dose-escalation trialGroup 1 (*N* = 5): oral miltefosine 50 mg every second day\
Group 2 (*N* = 5): miltefosine 100 mg every second day\
Group 3 (*N* = 5): miltefosine 100 mg/day\
Group 4 (*N* = 5): miltefosine 150 mg/day\
Group 5 (*N* = 5): miltefosine 250 mg/day\
Group 6 (*N* = 5): miltefosine 250 mg/day\
Treatment was given for 28 daysCR at 8-month follow-up: 40, 20, 100, 80, 100 and 100 %, respectivelyJha et al. \[[@CR128]\]India; *L.* *donovani*Open-label phase II miltefosine dose-finding trialGroup 1 (*N* = 30): oral miltefosine 50 mg/day for 6 weeks\
Group 2 (*N* = 30): miltefosine 50 mg/day for 1 week followed by 150 mg/day for 3 weeks\
Group 3 (*N* = 30): miltefosine 100 mg/day for 4 weeks\
Group 4 (*N* = 30): miltefosine 100 mg/day for 1 week followed by 150 mg/day for 3 weeksCR at 6-month follow-up: 93, 93, 97 and 97 %, respectivelySundar et al. \[[@CR18]\]India; *L.* *donovani*Phase II comparative clinical trial of different doses of miltefosineGroup 1 (*N* = 17): oral miltefosine 100 mg/day for 28 days\
Group 2 (*N* = 18): miltefosine 150 mg/day for 28 days\
Group 3 (*N* = 10): miltefosine 200 mg/day for 28 daysCR at 6-month follow-up: 94, 100 and 100 %, respectivelySundar et al. \[[@CR19]\]India; *L.* *donovani*Comparative study between different courses of miltefosineGroup 1 (*N* = 18): oral miltefosine 100 mg/day for 14 days\
Group 2 (*N* = 18): miltefosine 100 mg/day for 21 days\
Group 3 (*N* = 18): miltefosine 100 mg/day for 28 daysCR at 6-month follow-up: 88, 100 and 100 %, respectivelySundar et al. \[[@CR129]\]India*; L.* *donovani*Randomized open-label comparative study between miltefosine and ABGroup 1 (*N* = 299): oral miltefosine 50 or 100 mg/day\
Group 2 (*N* = 99): AB 1 mg/kg/day IV, total 15 injectionsCR at 6-month follow-up: ITT 95 and 97 %, respectively; PP 97 and 100 %, respectivelySundar et al. \[[@CR20]\]India; *L.* *donovani*Pilot paediatric open-label phase I/II dose-ranging study of miltefosineGroup 1 (*N* = 21): oral miltefosine 1.5 mg/kg/day for 28 days\
Group 2 (*N* = 18): miltefosine 2.5 mg/kg/day for 28 daysCR at 6-month follow-up: ITT 90 and 83 %, respectively; PP 90 and 88 %, respectivelyBhattacharya et al. \[[@CR21]\]India; *L.* *donovani*Multicentre paediatric phase II trial of miltefosine in children aged 2--11 years*N* = 80: oral miltefosine 2.5 mg/kg/day for 28 daysCure rate at 6-month follow-up: 94 %Ritmeijer et al. \[[@CR29]\]Ethiopia; *L.* *donovani*Unblinded randomized comparative trialGroup 1 (*N* = 290): oral miltefosine 100 mg/day for 28 days\
Group 2 (*N* = 254): SSG 20 mg Sb^v+^/kg/day IM for 30 daysCR at 6-month follow-up: 60 and 65.2 %, respectively; in non-HIV infected patients: 75.6 and 77.4 %, respectivelySingh et al. \[[@CR22]\]India; *Leishmania* sp. not isolated (most probably *L.* *donovani*)Prospective multicentre cross-sectional studyGroup 1 (*N* = 44): patients who had not received a prior antileishmanial drug received oral miltefosine 2.5 mg/kg/day, maximum 100 mg/day, for 28 days\
Group 2 (*N* = 20): patients who had received a 30-day course of SSG (20 mg Sb^v+^/kg/day) received miltefosine 2.5 mg/kg/day, maximum 100 mg/day, for 28 days\
Group 3 (*N* = 38): patients who had not received a prior antileishmanial drug received AB 1 mg/kg IV for 15 days\
Group 4 (*N* = 23): patients who had received a 30-day course of SSG (20 mg Sb^v+^/kg/day) received AB 1 mg/kg IV for 15 daysCR at 6-month follow-up: ITT and PP 93.2, 95, 92.1 and 91.3 %, respectivelyBhattacharya et al. \[[@CR130]\]India; *L.* *donovani*Phase IV open-label single-arm trial*N* = 1,132: oral miltefosine 100 mg/day for 28 days (age ≥12 years, bodyweight ≥25 kg); 50 mg/day for 28 days (age ≥12 years, bodyweight \<25 kg); 2.5 mg/kg/day for 28 days (age 2--11 years)CR at 6-month follow-up: PP 96.6 % in adults and 93.6 % in childrenRahman et al. \[[@CR23]\]Bangladesh; *Leishmania* sp. not isolated (most probably *L.* *donovani*)Open-label single-group trial*N* = 977: oral miltefosine for 28 days at doses of 2.5 mg/kg (age ≤12 years), 50 mg/day (age \>12 years, bodyweight \<25 kg), 100 mg/day (age \>12 years, bodyweight ≥25 kg)Cure rate at 6-month follow-up: PP 85 %Sundar et al. \[[@CR24]\]India; *Leishmania* sp. not isolated (most probably *L.* *donovani*)Open-label non-comparative study*N* = 567: oral miltefosine for 28 days, in a directly observed manner at doses of 50 mg (bodyweight \<25 kg), 100 mg (bodyweight ≥25 kg) or 2.5 mg per kg (age \<12 years)Cure rate at 6-month follow-up: 90.3 %Bhattacharya et al. \[[@CR21]\]India; *L.* *donovani*Multicentre paediatric phase II trial of miltefosine in children aged 2--11 years*N* = 80: oral miltefosine 2.5 mg/kg/day for 28 daysCure rate at 6-month follow-up: 94 %**Parenteral regimens***Pentavalent antimonials*Anabwani et al. \[[@CR32]\]Kenya*; L.* *donovani*Randomized trial of two dosage schedules of SSG in children and adultsGroup 1 (*N* = 26): 20 mg Sb^v+^/kg/day IM for 28 days\
Group 2 (*N* = 28): 10 mg Sb^v+^/kg/day IM for 28 daysCR at 4-week follow-up: in children 100 % with high dose vs 60 % with lower dose; no differences in adultsThakur et al. \[[@CR35]\]India; *L.* *donovani*Randomized dose-finding trial of SSGGroup 1 (*N* = 58): 10 mg Sb^v+^/kg/day IM for 20 days\
Group 2 (*N* = 61): 10 mg Sb^v+^/kg/day IM for 40 days\
Group 3 (*N* = 62): 15 mg Sb^v+^/kg/day IM for 20 days\
Group 4 (*N* = 63): 15 mg/kg/day IM for 40 days\
Group 5 (*N* = 63): 20 mg Sb^v+^/kg/day IM for 20 days\
Group 6 (*N* = 64): 20 mg Sb^v+^/kg/day IM for 40 daysCR at 6-month follow-up: 57, 74, 68, 86, 81 and 92 %, respectivelyThakur et al. \[[@CR33]\]India*; L.* *donovani*Randomized trial of longer durations of SSGGroup 1 (*N* = 104): 20 mg Sb^v+^/kg/day IM for 20 days\
Group 2 (*N* = 104): 20 mg Sb^v+^/kg/day IM for 30 days\
Group 3 (*N* = 104): 20 mg Sb^v+^/kg/day IM for 40 daysCR at 6-month follow-up: 71, 86 and 94 %, respectively; the differences between groups 1--3 and 2--3 were significantSeaman et al. \[[@CR38]\]Sudan; *L.* *donovani*Randomized comparative trialGroup 1 (*N* = 99): SSG 20 mg Sb^v+^/kg/day IM for 30 days\
Group 2 (*N* = 101): SSG 20 mg Sb^v+^/kg/day + paromomycin 15 mg/kg/day IM for 17 daysCR: 95 % in group 2 at day 17; 93.4 % in group 1 at day 30Veeken et al. \[[@CR39]\]Sudan; *L.* *donovani*Randomized comparative trialGroup 1 (*N* = 271): Pentostam^®^ SSG 20 mg Sb^v+^/kg/day IM for 30 days\
Group 2 (*N* = 245): generic SSG 20 mg Sb^v+^/kg/day IM for 30 daysCR at 6-month follow-up: 91.3 and 95.9 %, respectivelyMueller et al. \[[@CR41]\]Uganda; *Leishmania* sp. not isolated (most probably *L.* *donovani*)Comparative study between two cohortsGroup 1 (*N* = 210): AB 1 mg/kg IV on alternate days during a period of 30 days\
Group 2 (historical cohort, Sep 2002--Apr 2003), *N* = 161): SSG 20 mg Sb^v+^/kg/day (no upper limit) for 30 daysCR after treatment: 92.4 and 95 %, respectivelyGradoni et al. \[[@CR43]\]11 endemic Mediterranean countries; *L.* *infantum*Retrospective study collecting information during 2005--2007 regarding efficacy of pentavalent antimonials at 12-month follow-upGreece (*N* = 20): MA 20 mg Sb^v+^/kg/day for 20--30 daysCure rate: ≥95 %Israel (*N* = 12): SSG 20 mg Sb^v+^/kg/day for 28 daysCure rate: \>95 %Morocco (*N* = 55): MA 20 mg Sb^v+^/kg/day for 28 daysCure rate: \>95 %Palestine (*N* = 15): SSG 20 mg Sb^v+^/kg/day for 28 daysCure rate: \>95 %Portugal (*N* not specified): MA 20 mg Sb^v+^/kg/day for 20--30 daysCure rate: \>95 %Spain (*N* not specified): MA 20 mg Sb^v+^/kg/day for 28 daysCure rate: \>95 %Tunisia (*N* = 52): MA 20 mg Sb^v+^/kg/day for 21--28 daysCure rate: 95 %Turkey (*N* = 36): MA 20 mg Sb^v+^/kg/day for 30 daysCure rate: 95 %Petrela et al. \[[@CR45]\]Albania; *Leishmania* sp. not isolated (most probably *L.* *infantum*)Retrospective study collecting information on children (aged 0--14 years) during 1995--2009*N* = 1,210: SSG 20 mg Sb^v+^/kg/day IM for 21--28 daysCure rate at 6- to 12-month follow-up: 99.3 %Hailu et al. \[[@CR42]\]Ethiopia; *Leishmania* sp. not isolated (most probably *L.* *donovani*)Retrospective study collecting information during Jan 2008--Feb 2009Group 1 (*N* = 30): patients from North Ethiopia\
Group 2 (*N* = 24): patients from South Ethiopia\
All received SSG 20 mg Sb^v+^/kg/day IM for 30 days, maximum daily dose 850 mgCR at 6-month follow-up: 80 and 100 %, respectively*Amphotericin* *B deoxycholate*Mishra et al. \[[@CR131]\]India; *L.* *donovani*Non-comparative study*N* = 15: AB 0.5 mg/kg/day IV for 28 daysCure rate at 14-month follow-up: 93 %Mishra et al. \[[@CR83]\]India; *L.* *donovani*Randomized controlled comparative trial in antimony-unresponsive patientsGroup 1 (*N* = 60): pentamidine 4 mg/kg/day IM on alternate days for 20 injections\
Group 2 (*N* = 60): AB 0.5 mg/kg IV on alternate days for 14 dosesCR at 6-month follow-up: 77 and 98 %, respectivelyThakur et al. \[[@CR52]\]India; *L.* *donovani*Non-comparative study in SSG-resistant patients*N* = 300: AB 1 mg/kg/day IV on alternate days, starting with 0.5 mg/kg, total dose 20 mg/kgCure rate at the end of the treatment: 99 %Thakur et al. \[[@CR132]\]India; *L.* *donovani*Randomized controlled comparative trialGroup 1 (*N* = 75): AB 1 mg/kg IV on alternate days, total dose 20 mg/kg\
Group 2 (*N* = 75): SSG 20 mg Sb^v+^/kg/day IM for 30 daysCR at 6-month follow-up: 100 and 80 %, respectivelyMishra et al. \[[@CR55]\]India; *L.* *donovani*Randomized comparative trialGroup 1 (*N* = 40): SSG 20 mg Sb^v+^/kg/day IM for 40 days\
Group 2 (*N* = 40): AB 0.5 mg/kg IV on alternate days for 14 dosesCR at 12-month follow-up: 62 and 100 %, respectivelyThakur et al. \[[@CR56]\]India; *L.* *donovani*Randomized dose-finding study of ABGroup 1 (*N* = 40): AB 1 mg/kg/day IV daily, total dose 20 mg/kg\
Group 2 (*N* = 40): AB 1 mg/kg/day IV on alternate days, total dose 20 mg/kgCR at 6-month follow-up: 100 % in both groupsThakur et al. \[[@CR133]\]India; *L.* *donovani*Dose-finding study of ABGroup 1 (*N* = 60): AB in incremental doses increasing to 1 mg/kg/day IV daily, total dose 20 mg/kg\
Group 2 (*N* = 60): AB in constant doses of 1 mg/kg/day IV, total dose 20 mg/kgCR at 6-month follow-up: 100 % in both groupsGiri \[[@CR134]\]India; *L.* *donovani*Non-comparative study of AB after pentamidine failure*N* = 25: AB 0.75 mg/kg IV on alternate days, total 15 infusionsCure rate at 12-month follow-up: 100 %Giri and Singh \[[@CR135]\]India; *L.* *donovani*Non-comparative study of AB after antimonial failure*N* = 100: AB 0.75 mg/kg IV on alternate days, total 15 infusionsCure rate at 12-month follow-up: 100 %Jha et al. \[[@CR51]\]India; *L.* *donovani*Dose-finding study of AB in multidrug-resistant cases*N* = 34: AB 1 mg/kg/day IV on alternate days, total 10--15 injectionsCure rate at 6-month follow-up: 91 %Thakur et al. \[[@CR136]\]India; *L.* *donovani*Randomized dose-finding study of ABGroup 1 (*N* = 96): AB 1 mg/kg/day IV for 20 days\
Group 2 (*N* = 96): AB 0.75 mg/kg/day IV for 20 days\
Group 3 (*N* = 96): AB 0.5 mg/kg/day IV for 20 daysCR at 6-month follow-up: 99, 91 and 79 %, respectivelyThakur et al. \[[@CR137]\]India; *L.* *donovani*Randomized dose-finding study of ABGroup 1 (*N* = 65): AB 1 mg/kg/day IV daily for 20 days (maximum dose 20 mg/kg)\
Group 2 (*N* = 65): escalating doses of AB for 5 days, then 1 mg/kg/day IV on alternate days for 43 daysCR at 6-month follow-up: 99 % in both groupsThakur et al. \[[@CR138]\]India; *L.* *donovani*Non-comparative dose-finding study of AB*N* = 938: AB 1 mg/kg/day IV for 20 daysCure rate at 6-month follow-up: 99.2 %Thakur and Ahmed \[[@CR54]\]India; *L.* *donovani*Non-comparative study of AB*N* = 309: 1 mg/kg/day IV for 20 daysCure rate at 6-month follow-up: 95.8 %Thakur and Narayan \[[@CR36]\]India; *L.* *donovani*Randomized comparative studyGroup 1 (*N* = 30): SSG 20 mg/Sb^v+^/kg/day IM for 28 days\
Group 2 (*N* = 30): AB 1 mg/kg/day IV for 20 daysCR at 6-month follow-up: 46.6 and 100 %, respectivelyToumi et al. \[[@CR57]\]Tunisia; *L.* *infantum*Retrospective comparative studyGroup 1 (*N* = 17): MA 20 mg/Sb^v+^/kg/day IV\
Group 2 (*N* = 5): AB 0.5--1 mg/kg/day IV\
Both treatments for an average of 25 daysCR at the end of the treatment: 95 and 100 %, respectivelyMueller et al. \[[@CR41]\]Uganda; *Leishmania* sp. not isolated (most probably *L;* *donovani*)Comparative study between two cohortsGroup 1 (*N* = 210): AB 1 mg/kg on alternate days for 30 days\
Group 2 (historical cohort Sep 2002--Apr 2003, *N* = 161): MA 20 mg Sb^v+^/kg/day IM (with no upper limit) for 30 daysCR after treatment: 92.4 and 95 %, respectivelySingh et al. \[[@CR53]\]Bihar, India; *Leishmania* sp. not isolated (most probably *L.* *donovani*)Randomized study in childrenGroup 1 (*N* = 302) AB 1 mg/kg/day IV daily for 15 days\
Group 2 (*N* = 303): same dose as in group 1 but on alternate daysCR at 6-month follow-up: 100 % in both groups; the duration of stay and cost of therapy were significantly lesser in group 1*Liposomal amphotericin* *B*Davidson et al. \[[@CR71]\]Italy; *L.* *infantum*Multicentre non-comparative study of LABGroup 1 (*N* = 10): 1--1.38 mg/kg/day IV for 21 days\
Group 2 (*N* = 10): 3 mg/kg/day IV for 10 days\
Group 3 (*N* = 11 immune-compromised patients): 1.38--1.85 mg/kg/day IV for 21 daysCR at 24-month follow-up: 100 % in groups 1 and 2; 8 of 11 patients in group 3 had relapsedSeamen et al. \[[@CR66]\]Sudan; *L.* *donovani*Open-label trial using different schedules of LABGroup 1 (*N* = 16): 3--5 mg/kg/day IV on days 0, 3 and 10\
Group 2 (*N* = 16): 3--5 mg/kg/day IV days 0, 3, 6, 8, 10 and 13\
Group 3 (*N* = 12): 4--5 mg/kg/day IV days 0, 2, 5 and 7CR at the end of treatment: 50, 88 and 64 %, respectivelyThakur et al. \[[@CR62]\]India; *L.* *donovani*Randomized open trial of different schedules of LABGroup 1 (*N* = 10): 2 mg/kg/day IV on days 1, 2, 3, 4, 5, 6 and 10\
Group 2 (*N* = 10): 2 mg/kg/day IV on days 1, 2, 3, 4 and 10\
Group 3 (*N* = 10): 2 mg/kg/day IV on days 1, 5 and 10CR at 12-month follow-up: 100 % in all groupsDavidson et al. \[[@CR72]\]Italy; *L.* *infantum*Open-label dose-finding study of different schedules of LABGroup 1 (*N* = 13): 4 mg/kg/day IV on days 1--5 and 10\
Group 2 (*N* = 42): 3 mg/kg/day IV on days 1--5 and 10\
Group 3 (*N* = 32): 3 mg/kg/day IV on days 1--4 and 10\
Group 4 (*N* = 1): 3 mg/kg/day IV on days 1--3 and 10CR at 12-month follow-up: 100, 97.6, 90.6 and 100 %, respectivelyThakur \[[@CR59]\]India; *L.* *donovani*Randomized clinical trialGroup 1 (*N* = 17): LAB 15 mg/kg IV single dose\
Group 2 (*N* = 17): AB 1 mg/kg/day IV for 20 daysCR at end of treatment: 100 % in both groupsSundar et al. \[[@CR63]\]India; *L.* *donovani*Open-label dose-finding study of different doses of LABGroup 1 (*N* = 46): 5 mg/kg IV single dose\
Group 2 (*N* = 45): 1 mg/kg/day IV for 5 daysCR at 6-month follow-up: 91 and 93 %, respectivelySundar et al. \[[@CR60]\]India; *L.* *donovani*Randomized double-blind dose-ranging multicentre trialGroup 1 (*N* = 28): LAB 0.75 mg/kg/day IV for 5 days\
Group 2 (*N* = 28): LAB 1.5 mg/kg/day IV for 5 days\
Group 3 (*N* = 28): LAB 3 mg/kg/day IV for 5 daysCR at 6-month follow-up: 89, 93 and 96 %, respectivelySundar et al. \[[@CR64]\]India; *L.* *donovani*Open-label non-comparative study*N* = 203: LAB 5 mg/kg IV single doseCure rate at 6-month follow-up: 90 %Syriopoulou et al. \[[@CR73]\]Greece; *L.* *infantum*Open-label study in children, with historical controlsGroup 1 (*N* = 41): LAB 10 mg/kg/day IV for 2 days\
Group 2 (*N* = 30): LAB 4 mg/kg/day IV for 5 days\
Group 3 (*N* = 52): MA 20 mg Sb^v+^/kg/day for 30 daysCR at 6-month follow-up: 97.6, 90 and 90.4 %, respectivelySundar et al. \[[@CR58]\]India; *L.* *donovani*Randomized clinical comparative trialGroup 1 (*N* = 51): AB 1 mg/kg/day IV on alternate days, total 15 doses\
Group 2 (*N* = 51): LAB 2 mg/kg IV for 5 days\
Group 3 (*N* = 51): amphotericin B lipid complex 2 mg/kg/day IV for 5 daysCR at 6-month follow-up: 96, 96 and 92 %, respectivelySinha et al. \[[@CR61]\]India; *Leishmania* sp. not isolated (most probably *L.* *donovani*)Observational cohort study (Jul 2007--May 2008)*N* = 251: LAB 5 mg/kg/day IV on days 0, 1, 4 and 9CR at 6-month follow-up: ITT 98.8 %; PP 99.6 %Sundar et al. \[[@CR65]\]India; *Leishmania* sp. not isolated (most probably *L.* *donovani*)Open-label randomized controlled non-inferiority trialGroup 1 (*N* = 304): LAB 10 mg/kg IV single dose\
Group 2 (*N* = 108): AB 1 mg/kg IV, 15 infusions on alternate days for 29 daysCR at 6-month follow-up: 95.7 and 96.3 %, respectively*Pentamidine*Thakur \[[@CR82]\]India; *L.* *donovani*Non-comparative trial in patients unresponsive to SSG*N* = 86: pentamidine 4 mg/kg/very IV or IM for 2--3 days, total 15 doses (total dose 60 mg/kg)Cure rate at 12-month follow-up: 93.4 %Thakur et al. \[[@CR86]\]India; *L.* *donovani*Randomized controlled comparative trialGroup 1 (*N* = 104): pentamidine 4 mg/kg IV three times weekly until aspirates from the spleen were free of parasites\
Group 2 (*N* = 104): pentamidine 4 mg/kg IV three times weekly + SSG 20 mg Sb^v+^/kg IM daily for 20 days\
Group 3 (*N* = 104): pentamidine 4 mg/kg IV three times weekly until aspirates from the spleen were free of parasites, followed by SSG 20 mg Sb^v+^ IM for 20 daysCR at 6-month follow-up: 78, 84 and 98 %, respectivelyMishra et al. \[[@CR83]\]India; *L.* *donovani*Randomized controlled comparative trialGroup 1 (*N* = 60): pentamidine 4 mg/kg IM on alternate days, total 20 doses\
Group 2 (*N* = 60): AB 0.5 mg/kg IV on alternate days, total 14 dosesCR at 6-month follow-up: 77 and 98 %, respectivelyDas et al. \[[@CR85]\]India; *L.* *donovani*Randomized controlled comparative trialGroup 1 (*N* = 80): pentamidine 2 mg/kg/day IM on alternate days + oral allopurinol 15 mg/kg/day in three divided doses for 30 days\
Group 2 (*N* = 78): pentamidine 4 mg/kg/day IM on alternate days for 30 daysCR at 6-month follow-up: 91.2 and 74.3 %, respectivelyDas et al. \[[@CR84]\]India; *L.* *donovani*Randomized controlled comparative trialGroup 1 (*N* = 41): AB 1 mg/kg/day IV on alternate days for 15 days\
Group 2 (*N* = 41): pentamidine 4 mg/kg/day IM on alternate days, total 15 dosesCR at 6-month follow-up: 92 and 73 %, respectively*Paromomycin*Chunge et al. \[[@CR92]\]Kenya; *L.* *donovani*Non-randomized comparative studyGroup 1 (*N* = 11): SSG 20 mg Sb^v+^/kg/day IM/IV\
Group 2 (*N* = 19): paromomycin 14--16 mg (11 mg base)/kg/day IM\
Group 3 (*N* = 23): SSG 20 mg Sb^v+^/kg/day IM/IV + paromomycin 14--16 mg (11 mg base)/kg/day IM\
All treatments were administered until the first negative spleen aspirate was obtained or for 20 consecutive days regardless of aspirate findingsCR at 6-month follow-up: 54.5, 79 and 87 %, respectivelySeaman et al. \[[@CR38]\]Sudan; *L.* *donovani*Randomized comparative trialGroup 1 (*N* = 99): SSG 20 mg Sb^v+^/kg/day IM for 30 days\
Group 2 (*N* = 101): SSG 20 mg IM Sb^v+^/kg/day + paromomycin 15 mg (11 mg base)/kg/day IM for 17 daysCR at 17 days after beginning treatment: 81 and 95 %, respectivelyJha et al. \[[@CR88]\]India*; L.* *donovani*Randomized controlled comparative trialGroup 1 (*N* = 30): paromomycin 12 mg/kg/day IM for 21 days\
Group 2 (*N* = 30): paromomycin 16 mg/kg/day IM for 21 days\
Group 3 (*N* = 30): paromomycin 20 mg/kg/day IM for 21 days\
Group 4 (*N* = 30): SSG 20 mg Sb^v+^/kg/day IM for 30 daysCR at 6-month follow-up: 76.7, 96.7, 96.7 and 63.3 %, respectivelySundar et al. \[[@CR89]\]India; *L.* *donovani*Randomized controlled phase III open-label comparative studyGroup 1 (*N* = 502): paromomycin 11 mg base/kg/day IM for 21 days\
Group 2 (*N* = 165) AB 1 mg/kg/day IV for 30 daysCR at 6-month follow-up: 94.6 and 98.8 %, respectivelyMelaku et al. \[[@CR93]\]Sudan; *L.* *donovani*Retrospective comparative studyGroup 1 (*N* = 1,178): SSG 20 mg Sb^v+^/kg/day IM for 30 days\
Group 2 (*N* = 3,085): paromomycin 15 mg (11 mg base)/kg/day IM + SSG 20 mg Sb^v+^/kg/day IM for 17 daysCR at the end of treatment: 92.4 and 97 %, respectivelySundar et al. \[[@CR90]\]India; *L.* *donovani*Randomized open-label studyGroup 1 (*N* = 217): paromomycin 11 mg base/kg/day IM for 14 days\
Group 2 (*N* = 112): paromomycin 11 mg base/kg/day IM for 21 daysCure rate at 6-month follow-up: 82--92.8 %Hailu et al. \[[@CR94]\]Sudan, Kenya and Ethiopia; *L.* *donovani*Open-label randomized comparative trialGroup 1 (*N* = 135): paromomycin 15 mg/kg/day IM for 21 days\
Group 2 (*N* = 135): SSG 20 mg Sb^v+^/kg/day IM or IV for 30 days\
Group 3 (*N* = 135): paromomycin 15 mg/kg/day IM + SSG 20 mg Sb^v+^/kg/day IM or IV for 17 daysCR at 6-month follow-up: 63.8 and 92.2 %, respectivelyMusa et al. \[[@CR95]\]Sudan; *L.* *donovani*Open-label randomized dose-finding studyGroup 1 (*N* = 21): paromomycin 20 mg (15 mg base)/kg/day IM for 21 days\
Group 2 (*N* = 21): paromomycin 15 mg (11 mg base)/kg/day IM for 28 daysCR at 6-month follow-up: 85.7 and 90.5 %, respectivelySinha et al. \[[@CR91]\]India; *Leishmania* sp. not isolated (most probably *L.* *donovani*)Phase IV open-label trial*N* = 506: paromomycin 11 mg base/kg/day IM for 21 daysCure rate at 6-month follow-up: 94.2 %Musa et al. \[[@CR101]\]East Africa; *Leishmania* sp. not isolated (most probably *L.* *donovani*)Open-label parallel-arm multicentre individually randomized controlled trialGroup 1 (*N* = 386): SSG 20 mg Sb^v+^/kg/day IM for 30 days\
Group 2 (*N* = 205): paromomycin 20 mg/kg/day IM for 21 days\
Group 3 (*N* = 381): SSG 20 mg Sb^v+^/kg/day IM + paromomycin 15 mg/kg/day IM, both administered for 17 daysCR at 6-month follow-up: ITT 94, 84.3 and 91.4 %, respectively; PP 94.5, 84.3 and 91.4 %, respectively*AB* amphotericin B deoxycholate, *ABLC* amphotericin B lipid complex, *IM* intramuscularly, *ITT* intention-to-treat analysis, *IV* intravenously, *LAB* liposomal amphotericin B, MA meglumine antimoniate, *PP* per protocol analysis, *SSG* sodium stibogluconate

### Oral Treatment {#Sec5}

#### Allopurinol and Azole Drugs (Fluconazole, Ketoconazole, Itraconazole) {#Sec6}

The experience in the treatment of VL with allopurinol is scarce, out of date and has yielded disparate results. It is based on series of cases where allopurinol was used mainly as a rescue treatment in combination with antimonials or azole drugs \[[@CR10]--[@CR12]\].

The efficacy of treatment with azole drugs (fluconazole, ketoconazole, itraconazole) was based on uncontrolled studies with discordant results \[[@CR13], [@CR14]\]. The occurrence of nephrotoxicity due to the combination of allopurinol and ketoconazole was rare, and this enabled them to be used with good results in renal transplant patients \[[@CR10], [@CR15], [@CR16]\].

In conclusion, there is little evidence to recommend the use of azole drugs or allopurinol in the treatment of VL. GRADE: CIII

#### Miltefosine {#Sec7}

Several clinical trials conducted 5--10 years ago showed good evidence of efficacy with miltefosine in VL in adults in India. Regimens of 2.5 mg/kg/day for 28 days have led to cure rates of 94--97 % \[[@CR17], [@CR18]\]. Some studies have demonstrated that shorter regimens can also be effective; however, those results cannot be generalized, because of the small numbers of cases included and the absence of severe cases in those studies \[[@CR19]\]. Similar results in children aged \<12 years have been published \[[@CR20], [@CR21]\], showing the same efficacy as that of amphotericin B deoxycholate in both newly treated and sodium stibogluconate-resistant patients \[[@CR22]\]. Therefore, miltefosine was proposed as a first-line drug for VL in India, Nepal and Bangladesh.

However, a single-group trial performed in 2011 in Bangladesh, which included both adults and children, achieved cure rates of 85 % with the standard miltefosine regimen \[[@CR23]\]. Another non-comparative study performed in 2012 in 567 adults treated with miltefosine in India showed a cure rate of 90.3 % at 6-month follow-up \[[@CR24]\].

Initially, development of miltefosine-resistant parasites was thought to be the reason for this decrease in the cure rates. In fact, resistance to miltefosine has been shown to be easily induced in vitro \[[@CR25], [@CR26]\]. However, two recent studies performed in Nepal and India in patients with VL treated with miltefosine showed similar in vitro miltefosine susceptibility (using an in vitro promastigote assay) in cured patients and in patients who relapsed \[[@CR27], [@CR28]\]. Moreover, in the Nepal study, the only significant risk factor that was found to be associated with relapse was age \<12 years, probably due to differences in children's immune response, drug pharmacokinetics, and exposure to antigens. Another relevant fact was that the relapse rates were 10 % at 6-month follow-up and 20 % at 12-month follow-up. Considering that most clinical trials report 6-month follow-up, these findings also highlight the need for a longer follow-up period to establish a cure rate for miltefosine \[[@CR27]\].

A clinical trial performed in Ethiopia in immunocompetent patients reported a 75.6 % cure rate \[[@CR29]\]. Reliable data on the efficacy of miltefosine in VL in the Mediterranean region and Latin America have not been published.

##### **Recommendation** {#d30e3155}

Miltefosine regimenGradeMiltefosine (orally) for 28 days: 2.5 mg/kg/day in children aged 2--11 years; 50 mg/day in those aged ≥12 years with bodyweight \<25 kg; 100 mg/day in those aged ≥12 years with bodyweight ≥25 kg; 150 mg/day in those aged ≥12 years with bodyweight \>50 kgAI: VL in the Indian subcontinent, caused by *L.* *donovani*BI: VL in East Africa, caused by *L.* *donovani*CIII: VL in the Mediterranean Basin and South America, caused by *L.* *infantum*

### Parenteral Treatment {#Sec8}

#### Pentavalent Antimonials {#Sec9}

Sodium stibogluconate (100 mg Sb^v+^/mL) and meglumine antimoniate (85 mg Sb^v+^/mL) are the two available formulations containing pentavalent antimonials.

They are currently considered the first-line drugs in different parts of the world, except in those zones where resistance has developed---fundamentally in the state of Bihar (India), where the resistance rates are approaching 60 % of all cases \[[@CR30]\].

The doses and durations of treatment regimens with antimonials have undergone constant changes over the years. Sodium stibogluconate was introduced in the late 1940s, becoming the first-line treatment for VL. It was initially administered at low doses of 10 mg/kg/day for 6--10 days \[[@CR31]\], but the occurrence of therapeutic failures required progressive increases in the dose and duration of treatment. In the 1980s, the first studies were done to determine the most effective dose \[[@CR32], [@CR33]\] and, on the basis of those studies, the WHO decided in 1982 that the daily dose should be increased to 20 mg Sb^v+^/kg but specified that the total daily dose should not exceed 850 mg \[[@CR34]\]. The choice of this limit was exclusively based on the quantity of Sb^v+^ contained in two Glucantime^®^ vials (each vial contains 5 mL with 85 mg Sb^v+^/mL) and on the fact that patient bodyweight did not exceed 45 kg in the studies that were initially reported \[[@CR32]\]. Despite the fact that this recommendation was for VL, it was also used for the treatment of other clinical forms of leishmaniasis. However, some studies were published in which it was argued that doses of greater than 850 mg Sb^v+^ per day were more effective \[[@CR35]\]. Regarding the duration of the treatment, the first studies increased the regimens to 20, 30 and 40 days \[[@CR32], [@CR33]\]. Despite the fact that longer treatments (40 days) had better response rates and fewer relapses, toxicity was not taken into account. However, treatment regimens of \>28 days resulted in cardiotoxicity rates of 8--17 % \[[@CR36]\]. Thus, in 1992, the final recommendation was parenteral (IM or intravenous \[IV\]) administration of 20 mg Sb^v+^/kg without a limit of 850 mg/day, for 28--30 days \[[@CR37]\].

In Africa, the first trials were undertaken in Kenya in 1983 and marked a watershed in the determination of the optimal dose of pentavalent antimonials \[[@CR32]\]. However, few new studies have been done since then. In the 1990s, a comparative study was performed in Sudan between sodium stibogluconate on its own versus sodium stibogluconate combined with paromomycin, with response rates that were higher with the combined treatment \[[@CR38]\]. Other studies in Kenya and Sudan have analysed the efficacy of generic sodium stibogluconate versus patented versions, without observing any significant differences \[[@CR39], [@CR40]\]. Indeed, the generic formulae, which have a lower cost, have allowed health authorities to administer the treatment to more people in defined endemic zones in Africa, which have low resources. In Uganda, a comparative study was done between a cohort of patients treated with amphotericin B deoxycholate and a historic cohort of patients treated with antimonials at a dose of 20 mg Sb^v+^/kg/day without imposing a limit, with response rates of 95 % upon finishing the treatment \[[@CR41]\]. A recent study conducted in Ethiopia demonstrated differences in the cure rates after 6 months between patients from the North and those from the South (80 versus 100 %), which was justified by the different rates of HIV co-infection (46.4 % of the patients from the North were HIV positive, while no HIV case was detected among patients from the South). Thus, the efficacy of antimonials in Ethiopia in immunocompetent patients seems to be very high \[[@CR42]\].

In the Mediterranean countries, VL is mainly produced by *L.* *infantum*. In this case, the therapeutic evidence is less solid, and within the same zone, therapeutic attitudes even vary from country to country. During the 1990s, antimonials were the first-line treatment in France, Greece, Italy, Malta, Spain, Portugal, Morocco, Algeria and Tunisia, with cure rates of 95 % in immunocompetent patients \[[@CR43]\]. However, the information collected from 11 countries in Southern Europe, Northern Africa and the Middle East in the 21st century reflect certain variations in treatment recommendations \[[@CR44]\]. In Morocco, Tunisia, Turkey and Palestine, antimonials at a dose of 20 mg Sb^v+^/kg/day were the first-line treatment; in Portugal, Spain, Greece and Italy, antimonials and amphotericin B deoxycholate preparations were the two options for first-line treatment (although antimonials were not administered to patients with severe immunosuppression, and preparations of liposomal amphotericin B were recommended for treatment of relapses after antimonials); in France, Italy and Cyprus, liposomal amphotericin B was the first-line treatment, and relapses were treated with different regimens of the same drug. A recently published study collected a total of 1,210 cases of VL in children aged 0--14 years in Albania from 1995 to 2009, and demonstrated that antimonials at a dose of 20 mg Sb^v+^/kg/day for 21--28 days continue to be effective, with a cure rate of 99 % \[[@CR45]\].

VL in the New World is produced by *L.* *infantum/chagasi*. One of the most affected zones is the north-east of Brazil, where 3,000--5,000 cases appear every year, usually at a young age \[[@CR46]\]. It is a zoonotic infection resulting in a high percentage of asymptomatic patients, in contrast to VL in India. Classically, the treatment of VL in Brazil was based on the use of antimonials, with a cure rate of up to 95 %, keeping amphotericin B deoxycholate as a second-line treatment \[[@CR47]\]. The recent Pan-American Health Organization (PAHO) guidelines for the treatment of leishmaniasis in the Americas has established sodium stibogluconate as one of the first-line treatments at a dose of 20 mg Sb^v+^/kg/day IM or IV for 30 days \[[@CR48]\].

##### **Recommendation** {#d30e3346}

Pentavalent antimonial regimenGradeSodium stibogluconate or meglumine antimoniate (IM or IV) 20 mg Sb^v+^/kg/day (upper limit 850 mg/day) for 28--30 daysAI: VL in Bangladesh and Nepal or in East Africa, caused by *L.* *donovani*AII: VL in children in the Mediterranean Basin, caused by *L.* *infantum*BII: VL in the Middle East and South America, caused by *L.* *infantum*EI: VL in India (except in Jharkhand, West Bengal, Uttar Pradesh states), caused by *L.* *donovani*

#### Amphotericin B Deoxycholate {#Sec10}

Amphotericin B deoxycholate has been used for treatment of visceral and mucocutaneous leishmaniasis in the New World \[[@CR49], [@CR50]\]. However, it was not until the beginning of the 1990s that the first clinical trials were undertaken for the treatment of VL in the Old World (India). These demonstrated response rates of 98--100 % \[[@CR50], [@CR51]\] as first-line treatment, and 92 % in those cases where antimonials had previously failed \[[@CR51], [@CR52]\]. In India, initially 99 % of all patients responded to regimens of 1 mg/kg/day given daily or on alternate days for up to 20 doses \[[@CR53], [@CR54]\]. Later, it was shown that it was also effective (with a cure rate of 100 %) at lower doses of 0.5 mg/kg/day, given on alternate days for up to 14 days \[[@CR55]\].

Later studies demonstrated that daily administration was equally tolerated and was as effective as administration on alternate days \[[@CR53], [@CR56]\]. Because of the high rate of resistance to antimonials in India, amphotericin B deoxycholate seems to be established nowadays as the first-line treatment.

However, in other geographical areas with low resistance to antimonials, the use of amphotericin B deoxycholate is not as widespread. In fact, in Europe, lipid preparations of amphotericin B are used as first-line treatment or in those cases where antimonials have previously failed \[[@CR44]\]. In Uganda, a cure rate of 92.4 % was obtained with amphotericin B deoxycholate at a dose of 1 mg/kg on alternate days for a period of 30 days, similar to the cure rate in a historical cohort treated with antimonials and without any difference in the occurrence of severe side effects \[[@CR41]\]. A retrospective study of five cases of VL in Tunisia treated with amphotericin B deoxycholate at a dose of 0.5--1 mg/kg/day for an average of 25 days obtained a 100 % response rate \[[@CR57]\].

The PAHO guidelines for the treatment of leishmaniasis in the Americas have established amphotericin B deoxycholate (1 mg/kg/day IV up to an 800 mg total dose) as one first-line drug \[[@CR48]\].

#### Liposomal Amphotericin B {#Sec11}

In India, at least 10 different regimens of liposomal amphotericin B have been tested and resulted in a diverse range of response rates \[[@CR58], [@CR59]\]. Administration regimens of 5 days with total doses of 3.75, 7.5 and 15 mg/kg have been tested, with response rates that increase in proportion to the dose: 89, 93 and 96 %, respectively \[[@CR60]\]. Regimens of a total dose of 20 mg/kg spread over 4 days have obtained a 98.8 % cure rate \[[@CR61]\]. However, another study found no differences between different dosages of 2 mg/kg/day for 7, 5 and 3 days, obtaining a cure rate of 100 % \[[@CR62]\]. There have also been tests with different regimens of a single dose with good results. One study compared a single dose of 5 mg/kg versus administration over 5 days, with cure rates of 90 and 93 %, respectively \[[@CR63]\]. Another study compared liposomal amphotericin B in a single dose of 15 mg/kg versus amphotericin B deoxycholate in a dose of 1 mg/kg/day for 20 days, with 100 % cure rates in both groups at the end of treatment \[[@CR59]\]. Likewise, other non-comparative studies found that a single dose of 7.5 mg/kg achieved cure rates of 96 % \[[@CR64]\]. More recently, another study demonstrated that a single dose of 10 mg/kg was as effective as the conventional regimen of amphotericin B deoxycholate, with response rates of 95.7 and 96.3 %, respectively \[[@CR65]\].

There is very little experience of liposomal amphotericin B in Eastern Africa, and the recommendations are based on results obtained in India. In Sudan, a total dose of 20 mg/kg was tested, with cure rates of 88 %, but a lower dose of 12 mg/kg obtained only a 50 % response rate \[[@CR66]\]. A later study, also performed in Sudan, supported the previous results in which a relatively high total dose of liposomal amphotericin B (15--49 mg/kg) was needed to cure Sudanese patients \[[@CR67]\]. However, in both studies, most of the patients had high parasite density, had previously relapsed or suffered other severe underlying diseases such as HIV or tuberculosis. A phase II clinical trial in Kenya demonstrated efficacy of 20 % with total doses of 6 mg/kg, 90 % with total doses of 10 mg/kg and 100 % with total doses of 14 mg/kg \[[@CR68]\]. More recently, a case was reported of a Kenyan immigrant in Australia who travelled to visit friends and relatives and who responded to liposomal amphotericin B at a total dose of 20 mg/kg over 5 days \[[@CR69]\]. Currently, a randomized, multicentre, non-inferiority clinical trial is being conducted in Eastern Africa. It aims to compare a multiple-dose regimen with a total dose of 21 mg/kg given as 3 mg/kg IV on days 1, 2, 3, 4, 5, 14 and 21, and expects to obtain 95 % efficacy with a single-dose regimen. On the basis of the previous experience in India and Kenya \[[@CR59], [@CR64], [@CR65]\], the trial will begin with a 7.5 mg/kg single-dose regimen and, if this regimen is found to be ineffective at the time of an interim analysis, patients will be re-randomized to receive a higher dose (10, 12.5 mg/kg up to a maximum of 15 mg/kg) \[[@CR70]\]. Thus, it is expected that higher doses are needed in Eastern Africa than in India.

In Southern Europe, doses of 3--5 mg/kg/day, up to a total of 20 mg/kg in different regimens, have been demonstrated to be effective in up to 99--100 % of patients \[[@CR71]\]. Total doses of 15, 18 and 24 mg/kg were tested in Italy, with response rates of 91, 98 and 100 %, respectively \[[@CR72]\]. In Greece, one study administered a total dose of 20 mg/kg in a short regimen of 2 days, with a cure rate of 98 %, versus 90 % when it was administered over 5 days \[[@CR73]\]. Because of the large number of published case series, there is an important accumulation of evidence regarding the use of liposomal amphotericin B in pediatric populations in Europe, with response rates \>97 % with total doses of 18--24 mg/kg in different regimens \[[@CR74], [@CR75]\]. It has been shown that liposomal amphotericin B reduces the average duration of hospitalization when compared with antimonials \[[@CR76]\] and that it was effective in those cases where antimonials had previously failed \[[@CR77]\] For all of these reasons, and despite the absence of randomized clinical trials, liposomal amphotericin B is considered a reference treatment in the case of VL in the Mediterranean countries in adults as well as in children \[[@CR78]\].

In Latin America, there is much less evidence. In Brazil, doses of 20 mg/kg have been proven to be effective \[[@CR68]\]. In Colombia, two cases were published, where treatment with antimonials had failed, but both cases responded to liposomal amphotericin B at a dose of 2 mg/kg/day for 21 days in one patient, and a dose of 0.6 mg/kg/day for 15 days in the other \[[@CR79]\]. The PAHO guidelines for treatment of leishmaniasis in the Americas have established liposomal amphotericin B (3--5 mg/kg/day IV for 3--6 days, with a total dose of 20 mg) as one of the first-line therapeutic options \[[@CR48]\].

#### Other Lipid Preparations of Amphotericin B {#Sec12}

There is little evidence about the other different lipid preparations of amphotericin B deoxycholate. In India, the efficacy of amphotericin B lipid complex was compared with those of amphotericin B deoxycholate and liposomal amphotericin B, without encountering any significant differences \[[@CR58]\].

Despite the efficacy of lipid preparations, especially highlighted by liposomal amphotericin B, and their lower toxicity than that of amphotericin B deoxycholate, they have the disadvantage of high cost, which is particularly important in low-income countries. However, some low-income countries in the Indian subcontinent (Bangladesh, Nepal) and in East Africa (Sudan, South Sudan, Ethiopia and Kenya) would have access to reduced-price liposomal amphotericin B (AmBisome) through the Gilead/WHO AmBisome donation programme. An attempt has been made to develop inexpensive lipid-containing amphotericin B deoxycholate by mixing it with commercially available lipid emulsions. A commercial standardized product of pre-formed amphotericin B lipid emulsion is licensed for use in VL in India, after obtaining a cure rate of 91.1 % with total doses of 9--15 mg/kg \[[@CR80]\]. A subsequent study comparing four different administration regimens of a 15 mg/kg total dose of amphotericin B lipid emulsion obtained not only good results in terms of the safety of the drug, but also cure rates of 100 % in patients who received a single dose of 15 mg/kg \[[@CR81]\]. Thus, administering amphotericin B lipid emulsion at a total dose of 15 mg/kg IV over 4 h in a single dose or spreading it over a daily dose of 5 mg/kg for three consecutive days is very effective (100 %) for the treatment of VL in India, caused by *L.* *donovani*. GRADE BII

##### **Recommendation** {#d30e3587}

RegimenGrade*Amphotericin B deoxycholate* Amphotericin B deoxycholate (IV) 0.7--1 mg/kg/day, on alternate days, for 15--20 dosesAI: VL in the Indian subcontinent, caused by *L.* *donovani*BII: VL in East Africa, caused by *L.* *donovani*BIII: VL in the Mediterranean Basin and Latin America, caused by *L.* *infantumLiposomal amphotericin B* (Regimen 1) liposomal amphotericin B (IV) [10 mg/kg]{.ul} for 1 or 2 dosesAI: (regimen 1 or regimen 2): VL in the Indian subcontinent, caused by *L.* *donovani* (Regimen 2) liposomal amphotericin B (IV) 3--5 mg/kg/day for 3--5 doses (total dose [15 mg/kg]{.ul})AII: (regimen 3 in adults and regimen 2 in children): VL in the Mediterranean Basin, caused by *L.* *infantum* (Regimen 3) liposomal amphotericin B (IV) 3--5 mg/kg/day for 3--10 doses (total dose [18--30 mg/kg]{.ul})BII: (regimen 4): VL in East Africa, caused by *L.* *donovani* (Regimen 4) liposomal amphotericin B (IV) 3--5 mg/kg/day for 6--10 doses (total dose [30 mg/kg]{.ul})CIII: (regimen 3): VL in South America, caused by *L.* *infantum*

#### Pentamidine {#Sec13}

When India faced the need to find alternatives to pentavalent antimonials, pentamidine was tested in VL-endemic areas. In the 1980s, pentamidine at a dose of 4 mg/kg three times weekly for 12--21 days had obtained a cure rate of 93 % \[[@CR82]\]. However, the response rate started to decrease after the 1990s to about 70--80 % in certain areas of India \[[@CR83]\]. Later studies compared it with other therapeutic options used in those areas, as is the case with amphotericin B deoxycholate, demonstrating that pentamidine was less effective \[[@CR84]\]. Other studies revealed that the response rate increased when pentamidine was combined with antimonials or allopurinol \[[@CR85], [@CR86]\].

In Eastern Africa, pentamidine proved to be effective in the treatment of patients in Sudan after pentavalent antimonials had previously failed \[[@CR87]\].

There is little literature about use of pentamidine in the Mediterranean area and Latin America.

The decrease in its efficacy, its serious and sometimes irreversible toxicity, and the availability of other therapeutic options have meant that use of pentamidine has practically been abandoned over the last 4--5 years.

#### Paromomycin (Aminosidine) {#Sec14}

In the 1990s, different clinical trials were conducted, injecting paromomycin either alone or in combination with pentavalent antimonials as treatment for VL in India (Bihar) and in Africa (Kenya and Sudan).

In the state of Bihar (India), a phase II study was developed to evaluate the effectiveness and tolerability of paromomycin compared with antimonials. The patients treated with paromomycin achieved response rates of 77--97 %, compared with 66 % for antimonials. In addition to this, paromomycin showed a lower incidence of side effects, which included ototoxicity and renal toxicity. For this reason, it was concluded from this study that paromomycin was an adequate second-line treatment in cases resistant to antimonials \[[@CR88]\]. These results led to the development of a phase III trial in Bihar from 2003 to 2004, where paromomycin was not inferior to amphotericin B deoxycholate, with final cure rates of 94.6 versus 98.8 %, respectively \[[@CR89]\]. Recently, a study comparing the efficacy of paromomycin 15 mg (11 mg base)/kg/day for 14 days versus 21 days reported the efficacy to be inferior at 14 days \[[@CR90]\]. Finally, a phase IV study investigating the safety and efficacy of paromomycin in 506 adult and child patients attending six clinical centres in the state of Bihar has been published. All patients were treated for 21 days with paromomycin 11 mg base/kg/day IM. The cure rate after 6 months was 94.2 %, with good tolerability. With the exception of an increase in liver function test parameters, which decreased towards baseline over time, paromomycin had a reasonably safe profile, including demonstrated safety and efficacy in paediatric patients and, though with limited data, in pregnant women \[[@CR91]\].

In Africa, the majority of studies performed have been based on comparisons between paromomycin and antimonials, or on a combination of both. In a study in Kenya, the cure rate of paromomycin at a dose of 11 mg base/kg/day (until obtaining a negative spleen puncture or until achieving 20 consecutive days of treatment) was 54.4 % \[[@CR92]\]. Later studies carried out in Sudan revealed that the addition of paromomycin to antimonials increased the cure rate to 95--97 % \[[@CR38], [@CR93]\]. Furthermore, a study conducted in Sudan, Kenya and Ethiopia compared the efficacy of paromomycin as monotherapy at a dose of 15 mg (11 mg base)/kg/day for 21 days, antimonials as monotherapy for 30 days or the combination of both for 17 days. An interim analysis showed that paromomycin monotherapy had efficacy of \<50 % 6 months after the end of treatment in Sudan. This treatment arm was discontinued, and the trial continued with a higher dose of paromomycin 20 mg/kg/day for 21 days. After 6 months, the overall response rates were 92.2 % with sodium stibogluconate and 63.8 % with paromomycin; however, the efficacy of paromomycin varied substantially between geographical areas, with cure rates of 14.3--46.7 % in Sudan, 80 % in Kenya and 75--96.6 % in Ethiopia \[[@CR94]\]. Faced with this low response in Sudan, a new comparative study was carried out with higher doses of paromomycin, either increasing the duration of treatment from 21 to 28 days or increasing the daily dose from 15 to 20 mg base. Both options proved to be more effective than the usual regimen of 15 mg (11 mg base)/kg/day for 21 days, with cure rates of 81 and 80 % with 15 and 30 mg/kg/day, respectively \[[@CR95]\].

There are no data for the Mediterranean and Latin America (Table [2](#Tab2){ref-type="table"}).

##### **Recommendation** {#d30e3788}

RegimenGrade*Pentamidine* Pentamidine isethionate (IM or IV) 4 mg/kg/day on alternate days or three times weekly for 15--20 dosesDI: VL in the Indian subcontinent, caused by *L.* *donovani*DIII: VL in East Africa, caused by *L.* *donovani*; VL in the Mediterranean Basin and Latin America, caused by *L.* *infantumParomomycin* (Regimen 1) paromomycin (IM) 15 mg (11 mg base)/kg/day for 21 daysAI: (regimen 1): VL in the Indian subcontinent, caused by *L.* *donovani* (Regimen 2) paromomycin (IM) 15 mg (11 mg base)/kg/day for 28 days or 20 mg (15 mg base)/kg/day for 21 daysBI: (regimen 2): VL in East Africa (Kenya and Ethiopia, with a lower response rate in Sudan), caused by *L.* *donovani*

Combination Therapy {#Sec15}
-------------------

Combined therapy has the following objectives: shortening the duration of treatment (which leads to fewer side effects and improved adherence to the regimen), lowering the cost of the treatment, stopping the development of resistance, and encouraging a cure, especially in complicated cases (Table [3](#Tab3){ref-type="table"}).Table 3Combination therapy for visceral leishmaniasisReferenceCountry; *Leishmania* spp.Type of studyRegimen administeredCure rate (CR)Chunge et al. \[[@CR92]\]Kenya; *L.* *donovani*Non-randomized comparative studyGroup 1 (*N* = 11): SSG 20 mg Sb^v+^/kg/day\
Group 2 (*N* = 19): paromomycin 14--16 mg (11 mg base)/kg/day\
Group 3 (*N* = 23): SSG 20 mg Sb^v+^/kg/day + paromomycin 14--16 mg (11 mg base)/kg/day\
All treatments were administered until the first negative spleen aspirate was obtained or for 20 consecutive days regardless of aspirate findingsCR at 6-month follow-up: 54.5, 79 and 87 %, respectivelyThakur et al. \[[@CR86]\]India; *L.* *donovani*Randomized controlled comparative trialGroup 1 (*N* = 104): pentamidine 4 mg/kg IV three times weekly until aspirates from the spleen were free of parasites\
Group 2 (*N* = 104): pentamidine 4 mg/kg IV three times weekly + SSG 20 mg Sb^v+^/kg IM daily for 20 days\
Group 3 (*N* = 104): pentamidine 4 mg/kg IV three times weekly until aspirates from the spleen were free of parasites, followed by SSG 20 mg Sb^v+^ IM for 20 daysCR at 6-month follow-up: 78, 84 and 98 %, respectivelyThakur et al. \[[@CR97]\]India; *L.* *donovani*Non-comparative study*N* = 22: paromomycin 16 mg (12 mg base)/kg/day + SSG 20 mg Sb^v+^/kg/day for 20 daysCR at 6-month follow-up: 81.8 %Seaman et al. \[[@CR38]\]Sudan; *L.* *donovani*Randomized comparative trialGroup 1 (*N* = 99): SSG 20 mg Sb^v+^/kg/day for 30 days\
Group 2 (*N* = 101): SSG 20 mg Sb^v+^/kg/day + paromomycin 15 mg/kg/day for 17 daysCR at day 17: 95 % of group 2; at day 30: 93.4 % of group 1Thakur et al. \[[@CR96]\]India; *L.* *donovani*Randomized comparative open-label trialGroup 1 (*N* = 52): paromomycin 12 mg/kg/day + SSG 20 mg Sb^v+^/kg/day IM for 21 days\
Group 2 (*N* = 48): paromomycin 18 mg/kg/day + SSG 20 mg Sb^v+^/kg/day for 21 days\
Group 3 (49 patients): SSG 20 mg Sb^v+^/kg/day for 21 daysCR at 6-month follow-up: 92.3, 93.8 and 53.1 %, respectivelyDas et al. \[[@CR85]\]India; *L.* *donovani*Randomized controlled comparative trialGroup 1 (*N* = 80): pentamidine 2 mg/kg/day IM on alternate days + oral allopurinol 15 mg/kg/day in three divided doses for 30 days\
Group 2 (*N* = 78): pentamidine 4 mg/kg/day IM on alternate days for 30 daysCR at 6-month follow-up: 91.2 and 74.3 %, respectivelyMelaku et al. \[[@CR93]\]Sudan; *L.* *donovani*Retrospective comparative studyGroup 1 (*N* = 1,178): SSG 20 mg Sb^v+^/kg/day for 30 days\
Group 2 (*N* = 3,085): paromomycin 15 mg (11 mg base)/kg/day + SSG 20 mg Sb^v+^/kg/day for 17 daysCR at the end of treatment: 92.4 and 97 %, respectivelySundar et al. \[[@CR98]\]India; *L.* *donovani*Randomized non-comparative studyGroup 1 (*N* = 45): LAB 5 mg/kg IV single dose\
Group 2 (*N* = 46): LAB 5 mg/kg IV single dose + oral miltefosine 100 mg/day for 10 days\
Group 3 (*N* = 45 patients): LAB 5 mg/kg IV single dose + oral miltefosine 100 mg/day for 14 days\
Group 4 (*N* = 45): LAB 3.75 mg/kg IV single dose + oral miltefosine 100 mg/day for 14 days\
Group 5 (*N* = 45): LAB 5 mg/kg IV single dose + oral miltefosine 100 mg/day for 7 daysCR at 9-month follow-up: 91, 98, 96, 96 and 98 %, respectivelySundar et al. \[[@CR99]\]India; *L.* *donovani*Open-label parallel-group non-inferiority randomized controlled trialGroup 1 (*N* = 634): AB 1 mg/kg IV on alternate days for 30 days (total dose 15 mg/kg)\
Group 2 (*N* = 160): LAB 5 mg/kg IV single dose + oral miltefosine 50 mg/day for 7 days\
Group 3 (*N* = 158): paromomycin 11 mg/kg once daily IM for 10 days\
Group 4 (*N* = 159): oral miltefosine 50 mg/day for 10 days + paromomycin 11 mg/kg once daily IM for 10 daysCR at 6-month follow-up: ITT 93.0, 97.5, 97.5 and 98.7 %, respectively; PP 98.6, 98.7, 98.7 and 98.7 %, respectivelySundar et al. \[[@CR100]\]India; *Leishmania* sp. not isolated (most probably *L.* *donovani*)Interventional non-randomized multicentre trial(*N* = 135): LAB 5 mg/kg IV single dose + oral miltefosine 2.5 mg/kg/day for 14 daysCR at 6-month follow-up: ITT 91.9 %; PP 97.6 %*AB* amphotericin B deoxycholate, *IM* intramuscularly, *ITT* intention-to-treat analysis, *IV* intravenously, *LAB* liposomal amphotericin B, *PP* per protocol analysis, *SSG* sodium stibogluconate

In India, one of several published studies regarding combined therapy was undertaken in patients who had not responded to pentavalent antimonials. It demonstrated favourable results in patients treated sequentially with pentamidine and antimonials \[[@CR86]\]. Another similar study also underlined the positive effect of the combination of pentamidine and allopurinol \[[@CR85]\]. Also, in India and in patients never treated before, the combination of paromomycin and antimonials administered in short regimens was more effective than the conventional and longer regimens of antimonials \[[@CR96], [@CR97]\]. A more recent study showed slightly greater efficacy with combinations of liposomal amphotericin B at 5 mg/kg/day in a single dose followed by different regimens of oral miltefosine, compared with liposomal amphotericin B at 5 mg/kg/day in a single dose (96--98 versus 91 %) \[[@CR98]\]. In a comparative study performed in India, all drug combinations that were tested (single-dose liposomal amphotericin B plus miltefosine for 7 days or paromomycin for 10 days or miltefosine plus paromomycin for 10 days) were non-inferior to the standard treatment (amphotericin B deoxycholate for 30 days); patients in the combination groups had fewer adverse events than did those assigned to standard treatment \[[@CR99]\]. Another recently published study, also carried out in India, assessed the combination of one single dose of liposomal amphotericin B 5 mg/kg and miltefosine 2.5 mg/kg/day for 14 days, and found that the final intention-to-treat cure rate was 91.9 %, whereas per protocol it was 97.6 % \[[@CR100]\].

In Eastern Africa, specifically Sudan, two studies demonstrated that paromomycin associated with antimonials (sodium stibogluconate) increased the response rate in comparison with sodium stibogluconate as monotherapy \[[@CR38], [@CR93]\]. In Kenya, a non-randomized trial compared paromomycin and sodium stibogluconate as monotherapy versus the combination of both, the latter being the most effective option \[[@CR92]\]. In a study performed in East Africa (Sudan, Ethiopia, Kenya and Uganda) monotherapy with paromomycin (20 mg/kg/day for 21 days) or with sodium stibogluconate (20 mg/kg/day for 30 days) was compared with combination therapy (paromomycin 15 mg/kg/day and sodium stibogluconate 20 mg/kg/day for 17 days). Combination therapy was a safe regimen and just as effective (cure rate 91.4 %) as antimonials on their own (cure rate 93.9 %), thus being a good option for treatment in Eastern Africa \[[@CR101]\].

A phase II, open-label, randomized, controlled clinical trial has recently been completed in East Africa; however, the results are yet to be published. The trial assessed whether a short combination of sodium stibogluconate (20 mg/kg/day IM or IV for 10 days) plus a single dose of liposomal amphotericin B (10 mg/kg on day 1), or oral miltefosine (2.5 mg/kg/day up to maximum of 150 mg for 10 days, starting on day 2) plus a single dose of liposomal amphotericin B (10 mg/kg on day 1), or oral miltefosine alone (2.5 mg oral up to maximum of 150 mg for 28 days) are effective in treating VL in non-HIV patients \[[@CR102]\].

### **Recommendation** {#d30e4385}

Combination regimenGrade(Regimen 1) liposomal amphotericin B (IV) 5 mg/kg single dose + miltefosine (orally) for 7--14 days: 2.5 mg/kg/day in children aged 2--11 years; 50 mg/day in those aged ≥12 years with bodyweight \<25 kg; 100 mg/day in those aged ≥12 years with bodyweight ≥25 kg; 150 mg/day in those aged ≥12 years with bodyweight ≥50 kgAI: (regimen 1 or regimen 2 or regimen 3): VL in the Indian subcontinent, caused by *L.* *donovani*\
AI: (regimen 4): VL in East Africa, caused by *L.* *donovani*(Regimen 2) liposomal amphotericin B (IV) 5 mg/kg single dose + paromomycin (IM) 15 mg (11 mg base)/kg/day for 10 days(Regimen 3) miltefosine (orally) for 10 days: as above + paromomycin (IM) 15 mg (11 mg base)/kg/day for 10 days(Regimen 4) sodium stibogluconate or meglumine antimoniate (IM or IV) 20 mg Sb^v+^/kg/day for 17 days (without an upper limit of 850 mg/day) + paromomycin (IM) 15 mg (11 mg base)/kg/day for 17 days

Therapy in HIV-Infected Patients {#Sec16}
--------------------------------

Atypical forms of presentation and frequent relapses have been described in immunosuppressed patients. Immunoglobulin deficits, autoimmune diseases, tumours, organ transplants, or use of corticosteroids, methotrexate or tumour necrosis factor inhibitors can cause immunosuppression. Co-infection with HIV hinders the therapeutic response, causing relapses to be frequent, especially in patients with CD+ cell counts \<200 cells/μL, progressively reducing the pharmacological options after every relapse.

There have been few clinical trials regarding the efficacy of treatment in patients co-infected with HIV, and the majority have been carried out in Europe (infections produced by *L.* *infantum*). There are still many unanswered questions as to which should be the drug of choice, and the dose, duration, maintenance therapy, prophylaxis and efficacy of combined therapies in co-infected patients (Table [4](#Tab4){ref-type="table"}).Table 4Therapy for leishmaniasis in patients with HIV co-infectionReferenceCountry; *Leishmania* spp.Type of studyRegimen administeredCure rate (CR)**Oral regimens***Miltefosine*Ritmeijer et al. \[[@CR29]\]Ethiopia; *Leishmania* sp. not isolated (most probably *L.* *donovani*)Randomized non-blinded clinical trialGroup 1 (*N* = 63): miltefosine 100 mg/day orally for 28 days\
Group 2 (*N* = 44): SSG 20 mg Sb^v+^/kg/day IM for 30 daysCR at 6-month follow-up: 46 and 56.8 %, respectively**Parenteral regimens***Pentavalent antimonials*Laguna et al. \[[@CR108]\]Spain; *Leishmania* sp. not isolated (most probably *L.* *infantum*)Prospective randomized open-label multicentre trialGroup 1 (*N* = 44): MA 20 mg/kg/day parenterally for 28 days\
Group 2 (*N* = 45): AB 0.7 mg/kg/day IV for 28 daysCR at the end of treatment: 65.9 and 62.6 %, respectivelyLaguna et al. \[[@CR109]\]Spain; *L.* *infantum*Multicentre open-label blinded centrally randomized trialGroup 1 (*N* = 18): ABLC 3 mg/kg/day IV for 5 days\
Group 2 (*N* = 20): ABLC 3 mg/kg/day IV for 10 days\
Group 3 (*N* = 19): MA 20 mg Sb^v+^/kg/day parenterally for 28 daysCR at the end of treatment: 33, 42 and 37 %, respectivelyRitmeijer et al. \[[@CR29]\]Ethiopia; *L.* *donovani*Unblinded randomized comparative trialGroup 1 (*N* = 290): miltefosine 100 mg/day orally for 28 days\
Group 2 (*N* = 254): SSG 20 mg Sb^v+^/kg/day IM for 30 daysCR at 6-month follow-up: 60 and 65.2 %, respectively; in non-HIV-infected patients: 75.6 and 77.4 %, respectivelyHailu et al. \[[@CR42]\]Ethiopia; *Leishmania* sp. not isolated (most probably *L.* *donovani*)Retrospective study collecting information during Jan 2008--Feb 2009Group 1 (*N* = 30): patients from North Ethiopia\
Group 2 (*N* = 24): patients from South Ethiopia\
All received SSG 20 mg Sb^v+^/kg/day IM for 30 days, maximum daily dose 850 mgCR at 6-month follow-up: 80 and 100 %, respectively*Amphotericin* *B deoxycholate, amphotericin* *B lipid complex and liposomal amphotericin* *B*Laguna et al. \[[@CR108]\]Spain; *Leishmania* sp. not isolated (most probably *L.* *infantum*)Prospective randomized open-label multicentre trialGroup 1 (*N* = 44): MA 20 mg/kg/day parenterally for 28 days\
Group 2 (*N* = 45): AB 0.7 mg/kg/day IV for 28 daysCR at the end of treatment: 65.9 and 62.6 %, respectivelyLaguna et al. \[[@CR109]\]Spain; *L.* *infantum*Randomized open-label blinded randomized trialGroup 1 (*N* = 18): ABLC 3 mg/kg/day IV for 5 days\
Group 2 (*N* = 20): ABLC 3 mg/kg/day IV for 10 days\
Group 3 (*N* = 19): MA 20 mg/kg/day IM/IV for 28 daysCR after treatment: 33, 42 and 37 %, respectivelyRitmeijer et al. \[[@CR112]\]Ethiopia; *Leishmania* sp. not isolated (most probably *L.* *donovani*)Retrospective cohort analysisGroup 1 (*N* = 94): HIV-negative\
Group 2 (*N* = 195): HIV-positive\
LAB 25--40.5 mg/kg IV (median 30 mg/kg)CR after treatment: 74.1 and 38 %, respectivelySinha et al. \[[@CR113]\]India; *Leishmania* sp. not isolated (most probably *L.* *donovani*)Retrospective cohort study*N* = 55: liposomal amphotericin B 20 mg/kg IV divided over 4 doses (days 1, 2, 5 and 10); in less advanced cases, the dose was given over 4 consecutive days (days 1--4), and for relapse after a previous full course, a total dose of 25 mg/kg was given in 5 doses (days 1, 2, 5, 10 and 15)Cure rate at 6-month follow-up: 100 %**Maintenance therapy**Ribera et al. \[[@CR118]\]Spain; *L.* *infantum*Retrospective non-randomized open-label trialGroup 1 (*N* = 20): No treatment\
Group 2 (*N* = 9): oral allopurinol 300 mg/8 h\
Group 3 (*N* = 17): MA 850 mg Sb^v+^ IM once monthlyFreedom from relapse at 12-month follow-up: 9, 21 and 93 %, respectivelyLopez-Velez et al. \[[@CR116]\]Spain; *L.* *infantum*Blinded randomized multicentre open-label trialGroup 1 (*N* = 8): ABLC 3--5 mg/kg/day IV every 3 weeks for 12 months\
Group 2 (*N* = 9): no treatmentFreedom from relapse at 12-month follow-up: 50 and 22.2 %, respectivelyMolina et al. \[[@CR117]\]Spain; *L.* *infantum*Prospective non-randomized non-controlled study*N* = 17: LAB 4 mg/kg/day IV for 5 days and once weekly for 5 more weeks (total 10 doses)Freedom from relapse at 12-month follow-up: 79.1 %*AB* amphotericin B deoxycholate, *ABLC* amphotericin B lipid complex, *IM* intramuscularly, *IV* intravenously, *LAB* liposomal amphotericin B, *MA* meglumine antimoniate, *SSG* sodium stibogluconate

### Oral Treatment {#Sec17}

#### Miltefosine {#Sec18}

Miltefosine has been used, but there is limited published clinical information about its efficacy, tolerability and safety in HIV patients. The optimal duration of treatment for primary infection or for relapsing cases has not been established. One of the few published reports took place in Europe, where miltefosine was used within the Compassionate Access Programme for those HIV patients in whom previous treatment for VL had failed. Although the initial cure rates were 64 %, almost all of the patients relapsed \[[@CR103]\]. In Ethiopia, a randomized, non-blinded clinical trial was performed, comparing oral miltefosine 100 mg/day for 28 days with sodium stibogluconate 20 mg/kg/day for 30 days in a high-prevalence HIV population. The authors concluded that miltefosine was safer but less effective than sodium stibogluconate in HIV-infected patients \[[@CR29]\]. Another publication has reported the use of miltefosine in the management of four co-infected patients in Spain. They were severely immunosuppressed patients whose previous treatment for VL with amphotericin B deoxycholate or meglumine antimoniate had failed. All of the patients seemed to respond with symptomatic improvement, but when treatment was discontinued, all of the patients relapsed \[[@CR104]\].

### Parenteral Treatment {#Sec19}

#### Pentavalent Antimonials {#Sec20}

Although the prevalence of HIV-VL co-infection seems to be progressively increasing in India, with rates \>2--5 % in some recent studies \[[@CR105], [@CR106]\], clear data on cure rates with antimonials in co-infected patients are not available. However, there are factors that could limit the use of antimonials for VL in HIV patients in India: firstly, the rate of resistance to pentavalent antimonials is high in India (especially in Bihar, observed in non HIV patients); and secondly, treatment regimens frequently need to be longer in HIV patients than in non-HIV patients, so this would probably increase the toxicity rates seen with antimonials.

Pentavalent antimonials have been used in co-infected patients at a dose of 20 mg Sb^v+^/kg/day for 28--30 days in different European case series, with response rates between 33 and 82 % and frequent relapses \[[@CR107]\]. In two clinical European trials, which compared meglumine antimoniate with amphotericin B deoxycholate and liposomal amphotericin B, the response rates recorded for antimonials were 65.9 and 37 % \[[@CR108], [@CR109]\].

In African data from Ethiopia, poor cure rates were also found, with only 43.5 % of HIV-positive patients being cured at 6-month follow-up \[[@CR110]\]. Better results were observed in another two studies performed in Ethiopian populations, with 65.2--78.6 % cure rates, but a higher proportion of non-HIV-infected patients were included in the analysis \[[@CR29], [@CR42]\].

#### Pentamidine Regimens {#Sec21}

There have been no clinical trials with pentamidine, and experience is limited to clinical cases where, on many occasions, a combination with other drugs was used \[[@CR111]\].

#### Amphotericin B, Amphotericin B Lipid Complex and Liposomal Amphotericin B Regimens {#Sec22}

Although amphotericin B deoxycholate is one of the first-line drugs in the treatment of VL, there has been only one comparative study in HIV-infected patients, which was carried out in Europe (Spain, *L.* *infantum*). This study demonstrated that at a dose of 0.7 mg/kg/day for 28 days (20 mg/kg total dose), amphotericin B deoxycholate was equally as effective in the initial cure and prevention of relapses as antimonials (cure rate 62.6 %) \[[@CR108]\].

A total dose of 30 mg/kg of amphotericin B lipid complex proved to be slightly superior to a total dose of 15 mg/kg amphotericin B lipid complex and to antimonials (20 mg Sb^v+^/kg/day for 28 days) in co-infected patients in a multicentre, open-label, blinded, randomized trial conducted in Europe (Spain. *L.* *infantum*). However, the response rate did not exceed 42 % \[[@CR109]\].

Two studies have been carried out with liposomal amphotericin B. One was in Ethiopia with a cohort of HIV-positive and -negative patients treated with liposomal amphotericin B (total dose 30 mg/kg), with a cure rate of 60 %. Relapses were treated with sodium stibogluconate (20 mg/kg/day for 30 days), increasing the final cure rate in co-infected patients to 83 %. However, 16 % of these patients died as a direct result of the toxicity of sodium stibogluconate, highlighting the excess of toxicity in HIV-positive patients \[[@CR112]\]. In India, another retrospective cohort study included recently diagnosed VL--HIV co-infected patients starting liposomal amphotericin B treatment at total doses of 20--25 mg/kg over 4--15 days. Excellent tolerability was observed, and initially all patients responded to the treatment, with final cure rate of 85 % after 1--2 years post-treatment. \[[@CR113]\]. It is known that relapses can be treated in a similar way, as no resistance to amphotericin B deoxycholate has been noted.

##### **Recommendation** {#d30e5105}

RegimenGrade*Miltefosine* (Regimen 1) miltefosine (orally) 100 mg day for 28 daysCI: VL--HIV in Ethiopia, caused by *L.* *donovaniPentavalent antimonials*Sodium stibogluconate or meglumine antimoniate (IM or IV) 20 mg Sb^v+^/kg/day (without an upper limit of 850 mg/day) for 28 daysBI: VL in the Mediterranean Basin, caused by *L.* *infantum*CI: VL in East Africa (Ethiopia), caused by *L.* *donovaniAmphotericin* *B, amphotericin* *B lipid complex, liposomal amphotericin* *B* Amphotericin B (IV) 0.7 mg/kg/day for 28 daysBI: VL--HIV in the Mediterranean Basin, caused by *L.* *infantum* Amphotericin B lipid complex (IV) total dose 30 mg/kgCI: VL--HIV in the Mediterranean Basin, caused by *L.* *infantum* Liposomal amphotericin B (IV) total dose 20--30 mg/kgBIII: VL--HIV in India and Ethiopia, caused by *L.* *donovani*

#### Paromomycin Regimens {#Sec23}

The efficacy of paromomycin has not been established, and it is considered to be a drug that fairly easily develops resistance \[[@CR5]\]. The different trials that have proven its efficacy involved combined therapies with other drugs and were carried out mainly in HIV-negative patients.

#### Combination Therapy {#Sec24}

There are no data regarding the efficacy of combined therapy in HIV patients. Nonetheless, many experts are in favour of combined therapy for patients with multiple relapses \[[@CR6]\]. Combinations of antimonials with other drugs such as allopurinol, ketoconazole, fluconazole, itraconazole or interferon-γ have been used, but with insufficient evidence to consolidate the recommendation \[[@CR114]\]. A case report from Italy described the safety and efficacy of the combination of liposomal amphotericin B (4 mg/kg/day for 5 consecutive days and on days 10, 14, 17, 31 and 38) and the growth factor recombinant human granulocyte/monocyte colony-stimulating factor (rHuGM-CSF) \[150 μg subcutaneously twice weekly for 12 consecutive weeks\] in an HIV-positive patient with VL. No side effects were observed, and after 2 years of follow-up the patient was still free from disease \[[@CR115]\].

#### Maintenance Therapy {#Sec25}

The data regarding maintenance therapy after a treated episode of VL in HIV-infected patients has fundamentally been developed in Europe, where zoonotic transmission occurs by *L.* *infantum*.

The only randomized clinical trial, which took place in Spain, reported that use of amphotericin B lipid complex as maintenance therapy administered at a dose of 3--5 mg/kg/day IV every 3 weeks for 12 months, versus no treatment at all, lowered the relapse rate from 50 to 22 % \[[@CR116]\]. Another prospective study, also carried out in Spain, analyzed the efficacy of maintenance therapy with liposomal amphotericin B at 4 mg/kg/day for 5 days and once weekly for 5 more weeks (total 10 doses), achieving up to 80 % patients being free of disease after 12 months of follow-up \[[@CR117]\].

Pentavalent antimonials were administered every 3--4 weeks as maintenance therapy in a study conducted in Spain. The rate of relapses reduced much more significantly than in those patients who either did not receive any treatment or who took allopurinol for the 12 months of follow-up \[[@CR118]\].

Pentamidine was used at a dose of 4 mg/kg/day every 2--4 weeks in HIV-positive patients with VL caused by *L.* *infantum*, without any evidence of relapses during the follow-up period \[[@CR119], [@CR120]\].

Five cases reported in a study performed in Portugal observed that the three patients who received miltefosine as secondary prophylaxis for 21, 14 and 12 months, respectively, remained disease free for a median period of 20 months. Miltefosine could be a good option for maintenance therapy until improvement of immune function (CD4+ cell count \>250/mm^3^), because of its long half-life and ease of oral administration. This could allow ambulatory treatment and even dose reductions, using an alternate-day regimen \[[@CR121]\].

Azole drugs could be effective in maintenance therapy, although there are no clinical trials to support this theory. The experience is based on series of cases where itraconazole was given at a dose of 600 mg/day for up to 24 months of treatment, without any relapses. The advantage of these drugs is their good tolerability and low toxicity, although there is a risk of developing resistant fungal infections \[[@CR122], [@CR123]\]. Itraconazole or fluconazole combined with allopurinol could be an option \[[@CR124], [@CR10]\].

Another relevant aspect to take into account is how long maintenance therapy should be continued. According to different authors, once the patient has recovered their immune function with highly active antiretroviral therapy (HAART) and the VL is quiescent, suspension of prophylaxis could then be considered when the CD4+ count has been maintained at \>200 cells/μL for more than 6 months \[[@CR125], [@CR126]\].

##### **Recommendation**\* {#d30e5324}

Maintenance regimenGrade(Regimen 1) amphotericin B lipid complex (IV) 3--5 mg/kg/day every 3 weeksAI: (regimen 1): VL in the Mediterranean Basin, caused by *L.* *infantum*(Regimen 2) meglumine antimoniate (IM or IV) 850 mg Sb^v+^ in adults every 4 weeksAII: (regimen 2): VL in the Mediterranean Basin, caused by *L.* *infantum*(Regimen 3) pentamidine isethionate (IV) 4 mg/kg/day every 2--4 weeksCIII: (regimen 3): VL in the Mediterranean Basin, caused by *L.* *infantum*\*Suspension of maintenance therapy could be considered after HAART when the patient is stable and the CD4+ has been maintained at \>200 cells/μL for \>6 months

Conclusions {#Sec26}
===========

Currently, the control of VL relies primarily on chemotherapy. The traditional treatment for VL used to be pentavalent antimonials, introduced in the late 1940s. However, the development of resistance, especially in India, with failure rates of up to 60 %, as well as their potential toxicity, made it necessary to seek new treatment options. Thus, since the 1980s, the use of amphotericin B deoxycholate has been introduced, especially in more developed countries. Progressively, and because of their efficacy and lower toxicity, lipid formulations of amphotericin have been gaining importance, becoming the first-choice treatment established by the US Food and Drug Administration (FDA). However, their elevated cost has somewhat limited their use, but since the introduction of the recent Gilead/WHO AmBisome donation programme to Bangladesh, Nepal, Sudan, South Sudan, Ethiopia and Kenya, this situation has improved. Several studies have demonstrated the efficacy of paromomycin as a cheap parenteral treatment with medium toxicity. Within the range of oral treatments, miltefosine has been fundamentally used on the Indian subcontinent. Combination therapy will ultimately became the best drug regimen for treating VL in many parts of the world.

Treatment of VL in HIV co-infected patients is less effective than in HIV-negative patients, and relapses are much more frequent. Within the available treatment options, amphotericin B deoxycholate and particularly lipid formulations seem to be the most effective. Meanwhile, it seems that standard treatment with antimonials should be avoided because of their high toxicity in HIV-positive patients. Another difficulty that is hard to manage in co-infected patients is the frequent relapses. There is very little evidence regarding which drugs, doses and durations to use for maintenance therapy. The common relapses and prolonged secondary prophylaxis regimens could favour the development of resistant strains, which limit therapeutic options even further and create an epidemiological issue in areas of anthroponotic VL transmission.
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